Business Context and Reporting Period
This Form 8-K is filed by OvaScience, Inc. (not Tempest Therapeutics, Inc.) on August 4, 2016. The report announces the financial results for the quarter ended June 30, 2016. The full details of the results are contained in a press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided filing text serves as a cover document and does not contain specific numerical data. Consequently, the following metrics are not available in this text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric; these figures are located in the referenced Exhibit 99.1.
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only references the announcement of results for the quarter ended June 30, 2016.
Guidance, Outlook, and Risks
The text contains no management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information in the report (including the press release) is not incorporated by reference into other filings except as expressly set forth.
Investor Verification Checklist
- Verify the correct registrant name is OvaScience, Inc., as the input metadata incorrectly listed "Tempest Therapeutics, Inc."
- Locate and review Exhibit 99.1 (Press Release dated August 4, 2016) to obtain actual revenue, cash position, and operational metrics.
- Confirm the specific financial performance for the quarter ended June 30, 2016, as this 8-K only announces the release of such data.